7700 E Arapahoe Rd., Centennial, 80112-1268, CO, USA medicalsciences@onlinescientificresearch.info

Progress in Medical Sciences ISSN: 2577 - 2996

Video Article

Impact Factor: 1.023*

Progress in Medical Sciences. 2021; 5(1):(53-113)

Covid Causing Thrombotic Thrombocytopenic Purpura

Zohra R. Malik, James R. Allen, Muhammad Mumin, Lelesse Mocio, Brandon Miller and Zareen Razaq

COVID-19 has been causing havoc for over a year now. As more cases of COVID have been diagnosed, we are beginning to see various sequelae emerge after patients contract the virus. Specifically, we have seen a patient develop Thrombotic Thrombocytopenic Purpura (TTP) after being diagnosed with COVID-19. Thrombotic thrombocytopenic purpura is a hematologic disorder in which an enzyme deficiency, specifically of metalloprotease ADAMTS-13, causes abnormal multimer formation with the consequences of fever, microangiopathic hemolytic anemia, thrombocytopenia, renal disease, and neurological abnormalities. The coronavirus (COVID-19) has been observed across the world since first emerging in 2019 in China. Although both diseases have been widely observed independently, the development of TTP shortly after contracting COVID has not frequently been reported [1, 2, 3]. Thus, we are bringing to light a case of a patient who developed TTP shortly after being diagnosed with COVID.